{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["32(2)"],"submitter":["de Haan-Du J"],"funding":["Groninger Universiteitsfonds (GUF)","Groninger Universiteitsfonds"],"pubmed_abstract":["<h4>Background</h4>Poor glycemic control prior to cancer diagnosis for patients with preexisting type 2 diabetes (T2DM) may predict a worse cancer diagnosis. We investigated the association between pre-diagnosis glycemic control and all-cause mortality in patients with T2DM who develop cancer.<h4>Methods</h4>This prospective cohort study linked data from three sources covering 1989 to 2019: a T2DM benchmarking database, the Netherlands Cancer Registry, and the Personal Records Database. We included patients with T2DM and incident primary breast, colorectal, or prostate cancer (stage 0-III), with target glycemic control defined according to Dutch guidelines. Analysis involved estimating the association between glycemic control and all-cause mortality with Cox proportional hazard models, acc"],"journal":["Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"],"pagination":["252-259"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9900319"],"repository":["biostudies-literature"],"pubmed_title":["The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care."],"pmcid":["PMC9900319"],"pubmed_authors":["Kleefstra N","Landman GWD","de Bock GH","Groenier KH","de Haan-Du J","Jalving M","Wauben-Spaetgens B"],"additional_accession":[]},"is_claimable":false,"name":"The Value of Glycemic Control Prior to Cancer Diagnosis on All-Cause Mortality among Patients with Type 2 Diabetes in Dutch Primary Care.","description":"<h4>Background</h4>Poor glycemic control prior to cancer diagnosis for patients with preexisting type 2 diabetes (T2DM) may predict a worse cancer diagnosis. We investigated the association between pre-diagnosis glycemic control and all-cause mortality in patients with T2DM who develop cancer.<h4>Methods</h4>This prospective cohort study linked data from three sources covering 1989 to 2019: a T2DM benchmarking database, the Netherlands Cancer Registry, and the Personal Records Database. We included patients with T2DM and incident primary breast, colorectal, or prostate cancer (stage 0-III), with target glycemic control defined according to Dutch guidelines. Analysis involved estimating the association between glycemic control and all-cause mortality with Cox proportional hazard models, acc","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-21T18:12:38.968Z","creation":"2025-04-05T17:07:11.678Z"},"accession":"S-EPMC9900319","cross_references":{"pubmed":["36442479"],"doi":["10.1158/1055-9965.EPI-22-0766"]}}